SCHEMBL3608988

SCHEMBL3608988

Cc1cc(Cl)c(Oc2c(C=O)c(C)nn2C)cc1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
SMN1; SMN2 Q16637 5/20 0.48
EGFR P00533 1/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
MAPT P10636 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 1/20 0.38
RHEB Q15382 1/20 0.38
PDCD1 Q15116 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
MAPK14 Q16539 1/20 0.36
PKM P14618 1/20 0.36
STAT3 P40763 1/20 0.36
HTT P42858 1/20 0.36
FFAR4 Q5NUL3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3607091 0.90 CYP1A2 (0.48) CYP1A2CYP2C9CYP2C19SMN1; SMN2EGFR
SCHEMBL3604504 0.86 RHEB (0.41) SMN1; SMN2NPC1RAB9AMAPTL3MBTL1
SCHEMBL3599357 0.86 CYP1A2 (0.45) CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1
SCHEMBL3607830 0.85 CYP1A2 (0.44) CYP1A2CYP2C9CYP2C19SMN1; SMN2EGFR
SCHEMBL3612420 0.83 SMN1; SMN2 (0.53) CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1
SCHEMBL3613667 0.82 CYP1A2 (0.43) CYP1A2CYP2C9CYP2C19SMN1; SMN2EGFR
SCHEMBL3616398 0.80 SMN1; SMN2 (0.46) CYP1A2CYP2C9CYP2C19SMN1; SMN2EGFR
SCHEMBL3616401 0.80 SMN1; SMN2 (0.46) CYP1A2CYP2C9CYP2C19SMN1; SMN2EGFR
SCHEMBL3617500 0.80 SMN1; SMN2 (0.50) CYP1A2CYP2C9CYP2C19SMN1; SMN2LMNA
SCHEMBL3604721 0.75 ALDH1A1 (0.43) CYP1A2CYP2C9CYP2C19SMN1; SMN2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R CYP1A2 137/4885CYP2C9 145/4885CYP2C19 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.